IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.208,78 -313,84 (-0,56%)
Greenwich LifeSciences, Inc. (GLSI)
Después del cierre:
Greenwich LifeSciences, Inc.
Building 14
3992 Bluebonnet Drive
Stafford, TX 77477
United States
832 819 3232
https://greenwichlifesciences.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 3
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Snehal S. Patel | CEO, CFO & Director | 1,09M | N/A | 1964 |
| Mr. Eric Rothe | Founder & Independent Director | 65,64k | N/A | 1976 |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | N/A | N/A | 1951 |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | N/A | N/A | 1966 |
| Dr. Christine T. Fischette Ph.D. | VP of Business Development | N/A | N/A | 1951 |
Descripción
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Gobierno corporativo
El ISS Governance QualityScore de Greenwich LifeSciences, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
